314 related articles for article (PubMed ID: 9438022)
1. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
[TBL] [Abstract][Full Text] [Related]
3. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
5. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydro-isoquinoline-based factor Xa inhibitors.
Kucznierz R; Grams F; Leinert H; Marzenell K; Engh RA; von der Saal W
J Med Chem; 1998 Dec; 41(25):4983-94. PubMed ID: 9836616
[TBL] [Abstract][Full Text] [Related]
8. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
[TBL] [Abstract][Full Text] [Related]
9. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
[TBL] [Abstract][Full Text] [Related]
10. Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
Choi-Sledeski YM; McGarry DG; Green DM; Mason HJ; Becker MR; Davis RS; Ewing WR; Dankulich WP; Manetta VE; Morris RL; Spada AP; Cheney DL; Brown KD; Colussi DJ; Chu V; Heran CL; Morgan SR; Bentley RG; Leadley RJ; Maignan S; Guilloteau JP; Dunwiddie CT; Pauls HW
J Med Chem; 1999 Sep; 42(18):3572-87. PubMed ID: 10479289
[TBL] [Abstract][Full Text] [Related]
11. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
Phillips GB; Buckman BO; Davey DD; Eagen KA; Guilford WJ; Hinchman J; Ho E; Koovakkat S; Liang A; Light DR; Mohan R; Ng HP; Post JM; Shaw KJ; Smith D; Subramanyam B; Sullivan ME; Trinh L; Vergona R; Walters J; White K; Whitlow M; Wu S; Xu W; Morrissey MM
J Med Chem; 1998 Sep; 41(19):3557-62. PubMed ID: 9733480
[No Abstract] [Full Text] [Related]
14. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
Shi Y; Sitkoff D; Zhang J; Han W; Hu Z; Stein PD; Wang Y; Kennedy LJ; O'Connor SP; Ahmad S; Liu EC; Seiler SM; Lam PY; Robl JA; Macor JE; Atwal KS; Zahler R
Bioorg Med Chem Lett; 2007 Nov; 17(21):5952-8. PubMed ID: 17855089
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors.
Yoshikawa K; Yoshino T; Yokomizo Y; Uoto K; Naito H; Kawakami K; Mochizuki A; Nagata T; Suzuki M; Kanno H; Takemura M; Ohta T
Bioorg Med Chem Lett; 2011 Apr; 21(7):2133-40. PubMed ID: 21345673
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.
Lazarova TI; Jin L; Rynkiewicz M; Gorga JC; Bibbins F; Meyers HV; Babine R; Strickler J
Bioorg Med Chem Lett; 2006 Oct; 16(19):5022-7. PubMed ID: 16876411
[TBL] [Abstract][Full Text] [Related]
17. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of acylguanidine FXa inhibitors.
O'Connor SP; Atwal K; Li C; Liu EC; Seiler SM; Shi M; Shi Y; Stein PD; Wang Y
Bioorg Med Chem Lett; 2008 Aug; 18(16):4696-9. PubMed ID: 18644722
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
